阿扎胞苷联合帕博利珠单抗治疗中危-1及以上风险骨髓增生异常综合征的II期研究
该II期试验评估阿扎胞苷联合帕博利珠单抗治疗中危-1及以上风险MDS的疗效与安全性,分初治和HMA失败两个队列。联合治疗毒性可控,部分患者有抗肿瘤活性,值得在一线进一步研究。
要点
- 常见毒性为肺炎32%、关节痛24%、便秘24%,43%需糖皮质激素处理irAE。
核心结论
- 阿扎胞苷联合帕博利珠单抗在高危MDS中安全性可控,并在部分患者中显示抗肿瘤活性。
- 该联合方案值得在一线治疗中进一步研究。
研究设计与样本
- II期临床试验,设两个队列:初治MDS患者17例和HMA失败患者20例。
主要发现
- 最常见毒性为肺炎32%、关节痛24%、便秘24%。
- 需糖皮质激素治疗的免疫相关不良事件占43%。
临床怎么用
- 联合方案可用于高危MDS患者,但HMA失败后疗效有限,需关注免疫相关不良反应管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Programmed cell death protein 1 (PD-1) and PD-ligand 1 (PD-L1) expression is upregulated in cluster of differentiation 34 (CD34)+ bone marrow cells from patients with myelodysplastic syndromes (MDS). Hypomethylating agent (HMA) treatment results in further increased expression of these immune checkpoints. We hypothesised that combining an anti-PD-1 antibody with HMAs may have efficacy in patients with MDS. To test this concept, we designed a phase II trial of the combination of azacitidine and pembrolizumab with two cohorts. In the 17 previously untreated patients, the overall response rate (ORR) was 76%, with a complete response (CR) rate of 18% and median overall survival (mOS) not reached after a median follow-up of 12·8 months. For the HMA-failure cohort (n = 20), the ORR was 25% and CR rate was 5%; with a median follow-up of 6·0 months, the mOS was 5·8 months. The most observed toxicities were pneumonia (32%), arthralgias (24%) and constipation (24%). Immune-related adverse events requiring corticosteroids were required in 43%. Overall, this phase II trial suggests that azacitidine and pembrolizumab is safe with manageable toxicities in patients with higher-risk MDS. This combined therapy may have anti-tumour activity in a subset of patients and merits further studies in the front-line setting.
引用
- Chien KS, Kim K, Nogueras-Gonzalez GM, et al. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021. PMID: 34340254. doi:10.1111/bjh.17689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。